<DOC>
	<DOCNO>NCT01874028</DOCNO>
	<brief_summary>To evaluate effect single dose trientine child ≥6 year adult patient Wilson 's disease .</brief_summary>
	<brief_title>A Phase 1 Study Assess Effects Body Single Dose Trientine Dihydrochloride Wilson 's Disease Patients</brief_title>
	<detailed_description>An open , single-dose study determine pharmacokinetics , safety oral administration trientine dihydrochloride child adult patient Wilson 's Disease . Blood sample take pre-dose 10 time-points post-dose investigate pharmacokinetic profile trientine dihydrochloride 12 hour intake study medication 20 patient .</detailed_description>
	<mesh_term>Hepatolenticular Degeneration</mesh_term>
	<mesh_term>Trientine</mesh_term>
	<criteria>1 . Children ≥ 6 year adult patient 2 . Confirmed diagnosis Wilson 's disease LeipzigScore &gt; 3 ( Ferenci et al 2003 ) 3 . Current treatment trientine dihydrochloride 4 . Signed informed consent include parental consent patient ≤ 18 year 5 . Agree remain study site1 PK measurement period . 1 . Known clinically significant allergy hypersensitivity drug , opinion investigator , may affect patient 's safety 2 . Have clinically significant condition would interfere collection interpretation study result would compromise patient 's health 3 . Women child bear potential use contraceptive , breastfeeding , pregnant woman 4 . Severe anaemia ( haemoglobin &lt; 9 mg/dL ) 5 . In judgment Investigator , likely noncompliant uncooperative study , unable cooperate language problem poor mental development 6 . Participation interventional clinical study time within 4 week prior study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Trientine</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>